Sheybani Natasha D, Yang Hu
Department of Biomedical Engineering, Virginia Commonwealth University, Richmond, VA23284, United States.
Department of Chemical & Life Science Engineering, Virginia Commonwealth University, Richmond, VA 23219, United States.
Chin Chem Lett. 2017 Sep;28(9):1817-1821. doi: 10.1016/j.cclet.2017.07.022. Epub 2017 Jul 26.
The eye is a highly complex, yet readily accessible organ within the human body. As such, the eye is an appealing candidate target for a vast array of drug therapies. Despite advances in ocular drug therapy research, the focus on pediatric ocular drug delivery continues to be highly underrepresented due to the limited number of degenerative ocular diseases with childhood onset. In this review, we explore more deeply the reasons underlying the disparity between ocular therapies available for children and for adults by highlighting diseases that most commonly afflict children (with focus on the anterior eye) and existing prognoses, recent developments in ocular drug delivery systems and nanomedicines for children, and barriers to use for pediatric patients.
眼睛是人体中一个高度复杂但又易于触及的器官。正因如此，眼睛成为了众多药物疗法极具吸引力的候选靶点。尽管眼部药物治疗研究取得了进展，但由于儿童期发病的退行性眼病数量有限，针对儿科眼部给药的关注仍然严重不足。在这篇综述中，我们通过重点介绍最常见于儿童的疾病（着眼于眼前部）以及现有预后情况、儿童眼部给药系统和纳米药物的最新进展，以及儿科患者使用的障碍，更深入地探讨了儿童和成人可用眼部疗法之间存在差异的根本原因。
